A Phase 2, Randomized, Open Label Study of AMDX-2011P as a Retinal Tracer in Participants With Primary Open Angle Glaucoma
Latest Information Update: 01 Aug 2024
At a glance
- Drugs AMDX-2011P (Primary)
- Indications Open-angle glaucoma
- Focus Adverse reactions
- Sponsors Amydis
Most Recent Events
- 30 Jul 2024 Planned End Date changed from 1 Jul 2024 to 1 Feb 2025.
- 30 Jul 2024 Planned primary completion date changed from 1 May 2024 to 1 Nov 2024.
- 23 Jan 2024 Status changed from planning to recruiting.